The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

被引：0
|
作者：
Oflas, M. [1 ]
Simsek, D. Has [1 ]
Sanli, Y. [1 ]
Kuyumcu, S. [1 ]
Isik, E. [1 ]
Karadogan, S. [1 ]
Basaran, M. [2 ]
Ekenel, M. [2 ]
Mudun, A. [1 ]
Ozkan, Z. G. [1 ]
机构：
[1] Istanbul Fac Med, Dept Nucl Med, Istanbul, Turkiye
[2] Istanbul Univ, Dept Med Oncol, Inst Oncol, Istanbul, Turkiye
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0553
引用
收藏
页码：S649 / S650
页数：2
相关论文
共 50 条
  • [21] Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT
    Roll, Wolfgang
    Bode, Axel
    Weckesser, Matthias
    Boegemann, Martin
    Rahbar, Kambiz
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (02) : 152 - 153
  • [22] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [23] Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy
    Jafari, Esmail
    Manafi-Farid, Reyhaneh
    Ahmadzadehfar, Hojjat
    Salek, Fatemeh
    Jokar, Narges
    Keshavarz, Ahmad
    Divband, GhasemAli
    Dadgar, Habibollah
    Zohrabi, Farshad
    Assadi, Majid
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2024, 63 (06): : 347 - 358
  • [24] Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer
    Soon, Yu Yang
    Marschner, Ian C.
    Schou, Manjula
    Hofman, Michael S.
    Emmett, Louise
    Davis, Ian D.
    Stockler, Martin R.
    Martin, Andrew J.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [25] Safety and response to177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Liu, Qingxing
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [26] Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients
    Kleiburg, Fleur
    de Geus-Oei, Lioe-Fee
    Spijkerman, Romy
    Noortman, Wyanne A.
    van Velden, Floris H. P.
    Manohar, Srirang
    Smit, Frits
    Toonen, Frank A. J.
    Luelmo, Saskia A. C.
    van der Hulle, Tom
    Heijmen, Linda
    EUROPEAN RADIOLOGY, 2025,
  • [27] Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer
    Tann, Mark
    Sims, Justin
    Auxier, Ashleigh
    Althouse, Sandra K.
    Salous, Tareq
    King, Jennifer
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 135 - 135
  • [28] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [29] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [30] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
12345